Literature DB >> 22427201

Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia.

Eugene Khandros1, Christopher S Thom, Janine D'Souza, Mitchell J Weiss.   

Abstract

Cells remove unstable polypeptides through protein quality-control (PQC) pathways such as ubiquitin-mediated proteolysis and autophagy. In the present study, we investigated how these pathways are used in β-thalassemia, a common hemoglobinopathy in which β-globin gene mutations cause the accumulation and precipitation of cytotoxic α-globin subunits. In β-thalassemic erythrocyte precursors, free α-globin was polyubiquitinated and degraded by the proteasome. These cells exhibited enhanced proteasome activity, and transcriptional profiling revealed coordinated induction of most proteasome subunits that was mediated by the stress-response transcription factor Nrf1. In isolated thalassemic cells, short-term proteasome inhibition blocked the degradation of free α-globin. In contrast, prolonged in vivo treatment of β-thalassemic mice with the proteasome inhibitor bortezomib did not enhance the accumulation of free α-globin. Rather, systemic proteasome inhibition activated compensatory proteotoxic stress-response mechanisms, including autophagy, which cooperated with ubiquitin-mediated proteolysis to degrade free α-globin in erythroid cells. Our findings show that multiple interregulated PQC responses degrade excess α-globin. Therefore, β-thalassemia fits into the broader framework of protein-aggregation disorders that use PQC pathways as cell-protective mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427201      PMCID: PMC3369615          DOI: 10.1182/blood-2011-12-397729

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Globin synthesis in fractionated Normoblasts of beta-thalassemia heterozygotes.

Authors:  W G Wood; G Stamatoyannopoulos
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

2.  Autophagy driven by a master regulator of hematopoiesis.

Authors:  Yoon-A Kang; Rajendran Sanalkumar; Henriette O'Geen; Amelia K Linnemann; Chan-Jung Chang; Eric E Bouhassira; Peggy J Farnham; Sunduz Keles; Emery H Bresnick
Journal:  Mol Cell Biol       Date:  2011-10-24       Impact factor: 4.272

3.  Immature erythroblasts with extensive ex vivo self-renewal capacity emerge from the early mammalian fetus.

Authors:  Samantha J England; Kathleen E McGrath; Jenna M Frame; James Palis
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

Review 4.  Protein quality control during erythropoiesis and hemoglobin synthesis.

Authors:  Eugene Khandros; Mitchell J Weiss
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

5.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 6.  Thalassemia: the consequences of unbalanced hemoglobin synthesis.

Authors:  D G Nathan; R B Gunn
Journal:  Am J Med       Date:  1966-11       Impact factor: 4.965

7.  Turnover of excess hemoglobin alpha chains in beta-thalassemic cells is ATP-dependent.

Authors:  J R Shaeffer
Journal:  J Biol Chem       Date:  1983-11-10       Impact factor: 5.157

8.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 9.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

Review 10.  Proteasome inhibitors in cancer therapy.

Authors:  Ugo Testa
Journal:  Curr Drug Targets       Date:  2009-10       Impact factor: 3.465

View more
  38 in total

1.  Do not super-excess me!

Authors:  Stefano Rivella
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

2.  The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability.

Authors:  Jacky Chung; Daniel E Bauer; Alireza Ghamari; Christopher P Nizzi; Kathryn M Deck; Paul D Kingsley; Yvette Y Yien; Nicholas C Huston; Caiyong Chen; Iman J Schultz; Arthur J Dalton; Johannes G Wittig; James Palis; Stuart H Orkin; Harvey F Lodish; Richard S Eisenstein; Alan B Cantor; Barry H Paw
Journal:  Sci Signal       Date:  2015-04-14       Impact factor: 8.192

3.  An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.

Authors:  Michael Dussiot; Thiago T Maciel; Aurélie Fricot; Céline Chartier; Olivier Negre; Joel Veiga; Damien Grapton; Etienne Paubelle; Emmanuel Payen; Yves Beuzard; Philippe Leboulch; Jean-Antoine Ribeil; Jean-Benoit Arlet; Francine Coté; Geneviève Courtois; Yelena Z Ginzburg; Thomas O Daniel; Rajesh Chopra; Victoria Sung; Olivier Hermine; Ivan C Moura
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

4.  Mitophagy is increased during erythroid differentiation in β-thalassemia.

Authors:  Limei Wu; Wei Xu; Luhong Xu; Qian Kong; Jianpei Fang
Journal:  Int J Hematol       Date:  2016-10-28       Impact factor: 2.490

5.  scyllo-Inositol promotes robust mutant Huntingtin protein degradation.

Authors:  Aaron Y Lai; Cynthia P Lan; Salwa Hasan; Mary E Brown; Joanne McLaurin
Journal:  J Biol Chem       Date:  2013-12-18       Impact factor: 5.157

Review 6.  Anemia: progress in molecular mechanisms and therapies.

Authors:  Vijay G Sankaran; Mitchell J Weiss
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

Review 7.  The Logic of the 26S Proteasome.

Authors:  Galen Andrew Collins; Alfred L Goldberg
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

8.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 9.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

10.  Pathophysiology and Clinical Manifestations of the β-Thalassemias.

Authors:  Arthur W Nienhuis; David G Nathan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.